Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

1.54
-0.0500-3.14%
Post-market: 1.570.0300+1.95%19:34 EST
Volume:2.20M
Turnover:3.43M
Market Cap:408.66M
PE:-23.77
High:1.60
Open:1.59
Low:1.53
Close:1.59
52wk High:4.08
52wk Low:1.45
Shares:265.37M
Float Shares:259.80M
Volume Ratio:0.61
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0648
EPS(LYR):-0.3290
ROE:-553.45%
ROA:4.80%
PB:9.83
PE(LYR):-4.68

Loading ...

Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 02

Top Midday Gainers

MT Newswires Live
·
Dec 02

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Benzinga_recent_news
·
Dec 01

Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal

MT Newswires Live
·
Dec 01

BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline

Reuters
·
Dec 01

BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097

Reuters
·
Dec 01

Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics

Dow Jones
·
Dec 01

Top Premarket Gainers

MT Newswires Live
·
Dec 01

Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio

Reuters
·
Dec 01

Akebia Announces Establishment of Rare Kidney Disease Pipeline

THOMSON REUTERS
·
Dec 01

Akebia Therapeutics: Phase 2 Basket Trial Planned to Evaluate Complement Inhibitor in Multiple Rare Kidney Disease Indications

THOMSON REUTERS
·
Dec 01

Akebia Therapeutics Inc: Both Trials Planned to Start Treating Subjects in 2026

THOMSON REUTERS
·
Dec 01

Akebia Therapeutics: Acquires Next Generation Tissue-Targeted C3d-Factor H Fusion Protein Complement Inhibitor From Q32 Bio

THOMSON REUTERS
·
Dec 01

Akebia Therapeutics Inc: Phase 2 Trial of Praliciguat Initiated in Focal Segmental Glomerulosclerosis (Fsgs)

THOMSON REUTERS
·
Dec 01

Q32 Bio Inc - Eligible for up to $592 Mln Including Royalties

THOMSON REUTERS
·
Dec 01

Q32 Bio Inc - $12 Mln Payments Expected to Extend Cash Runway Into Second Half of 2027

THOMSON REUTERS
·
Dec 01

Press Release: Q32 Bio Sells Complement Inhibitor ADX-097

Dow Jones
·
Dec 01

Akebia Therapeutics Updates License Agreement with Medice for Vafseo Supply and Manufacturing

Reuters
·
Nov 17

BRIEF-Akebia Therapeutics Inc Says On Nov 12, Co And Medice Amend License Agreement

Reuters
·
Nov 17